?14 Aug 2018 09:01
Declan Doogan, CEO of Portage, commented "We are excited about acquiring an additional portfolio of immuno-oncology assets. The SalvaRx team has assembled a diverse group of pharmaceutical products, and has demonstrated success in getting new products into the clinic. We have made an early investment in Stimunity, another Immuno-oncology platform, which is very complementary to SalvaRx's products. With the combined team, we hope to accelerate the timeline to the clinic for these new drugs, and see if we can repeat the success achieved with Biohaven."
Dr. Declan Doogan, M.D., FRCP, has been the Chief Executive Officer at Portage Biotech Inc. since June 4, 2013. Dr. Doogan is a Co-Founder and Managing Director at Juvenescence Limited.